Drugs + Prices
Label
Drugs + Prices
Name
Drugs + Prices
Focus
Actions
Incoming Resources
- Subject of11
- Medicare payments for currently covered prescription drugs, hearing before the Subcommittee on Health of the Committee on Ways and Means, House of Representatives, One Hundred Seventh Congress, second session, October 3, 2002
- State of competition in the pharmacy benefits manager and pharmacy marketplaces, hearing before the Subcommittee on Regulatory Reform, Commercial and Antitrust Law of the Committee on the Judiciary, House of Representatives, One Hundred Fourteenth Congress, first session, November 17, 2015
- Ryan White Care Act, improved oversight needed to ensure AIDS drug assistance programs obtain best prices for drugs : report to congressional requesters
- Emerging health care issues, follow-on biologic drug competition
- Prescription drug pricing in the private sector
- Pay-for-delay, how drug company pay-offs cost consumers billions : an FTC staff study
- Prescription drugs, an overview of approaches to negotiate drug prices used by other countries and U.S. private payers and federal programs : testimony before the Committee on Finance, U.S. Senate, statement of John E. Dicken
- Medicare Part D, CMS has implemented processes to oversee plan finder pricing accuracy and improve website usability : report to the Special Committee on Aging, U.S. Senate
- Medicare Part D, prescription drug benefit, increasing use and access of affordable prescription drugs : a report of the Special Committee on Aging, United States Senate
- Ryan White Care Act, impact of legislative funding proposal on urban areas
- The $800 million pill, the truth behind the cost of new drugs, Merrill Goozner
Outgoing Resources
- Focus1
- Sub focus2